JPH09510979A - 内皮性機能障害の予防および治療用医薬製剤および医薬品 - Google Patents

内皮性機能障害の予防および治療用医薬製剤および医薬品

Info

Publication number
JPH09510979A
JPH09510979A JP7525343A JP52534395A JPH09510979A JP H09510979 A JPH09510979 A JP H09510979A JP 7525343 A JP7525343 A JP 7525343A JP 52534395 A JP52534395 A JP 52534395A JP H09510979 A JPH09510979 A JP H09510979A
Authority
JP
Japan
Prior art keywords
nitric oxide
stimulants
endothelial
compounds
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP7525343A
Other languages
English (en)
Japanese (ja)
Inventor
アルベヒト ノアク，アイケ
コユダ、ゲオルグ
Original Assignee
イーエスイーエス、ファルマ、ゲゼルシャフト、ミット、ベシュレンクテル、ハフツング
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by イーエスイーエス、ファルマ、ゲゼルシャフト、ミット、ベシュレンクテル、ハフツング filed Critical イーエスイーエス、ファルマ、ゲゼルシャフト、ミット、ベシュレンクテル、ハフツング
Publication of JPH09510979A publication Critical patent/JPH09510979A/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/556—Angiotensin converting enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
JP7525343A 1994-03-30 1995-03-28 内皮性機能障害の予防および治療用医薬製剤および医薬品 Pending JPH09510979A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE4410997A DE4410997A1 (de) 1994-03-30 1994-03-30 Pharmazeutische Zubereitungen und Arzneistoffe zur Prävention und Behandlung endothelialer Dysfunktionen
DE4410997.0 1994-03-30
PCT/DE1995/000421 WO1995026725A1 (de) 1994-03-30 1995-03-28 Pharmazeutische zubereitingen und arzneistoffe zur prävention und behandlung endothelialer dysfunktion

Publications (1)

Publication Number Publication Date
JPH09510979A true JPH09510979A (ja) 1997-11-04

Family

ID=6514213

Family Applications (1)

Application Number Title Priority Date Filing Date
JP7525343A Pending JPH09510979A (ja) 1994-03-30 1995-03-28 内皮性機能障害の予防および治療用医薬製剤および医薬品

Country Status (19)

Country Link
EP (1) EP0752858A1 (lt)
JP (1) JPH09510979A (lt)
CN (1) CN1150387A (lt)
BG (1) BG63073B1 (lt)
CA (1) CA2186783A1 (lt)
CZ (1) CZ283696A3 (lt)
DE (2) DE4410997A1 (lt)
EE (1) EE9600139A (lt)
FI (1) FI963883A0 (lt)
HU (1) HU220165B (lt)
IS (1) IS4365A (lt)
LT (1) LT4310B (lt)
LV (1) LV11666B (lt)
MX (1) MX9604434A (lt)
NO (1) NO964102D0 (lt)
PL (1) PL316528A1 (lt)
SI (1) SI9520047A (lt)
SK (1) SK121896A3 (lt)
WO (1) WO1995026725A1 (lt)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007507451A (ja) * 2003-10-03 2007-03-29 レイサー ソシエダッド アノニマ 環状糖の二硫化物、硫化物、スルホキシド及びスルホン誘導体とその使用方法
JP2013082693A (ja) * 2011-09-28 2013-05-09 Univ Of Tokushima ニトロソニフェジピン誘導体を有効成分とする動脈硬化症治療剤

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9423868D0 (en) * 1994-11-25 1995-01-11 Wellcome Found Compounds for use in medicine
DE19604361C2 (de) * 1996-02-07 1999-01-14 Sanol Arznei Schwarz Gmbh Verwendung gasdichter Primärpackmittel für pharmazeutische Zusammensetzungen
DE19654895C2 (de) * 1996-02-07 2000-07-27 Sanol Arznei Schwarz Gmbh Detektionsverfahren
DE19726812A1 (de) * 1997-06-25 1999-01-07 Isis Pharma Gmbh Neue Derivate des Pentaerythrits, deren Herstellung und Verwendung sowie Intermediate zur Synthese derselben
US5958926A (en) * 1996-11-01 1999-09-28 Nitromed, Inc. Nitrosated and nitrosylated phosphodiesterase inhibitor compounds, compositions and their uses
USRE37234E1 (en) 1996-11-01 2001-06-19 Nitromed, Inc. Nitrosated and nitrosylated phosphodiestrase inhibitor compounds, compositions and their uses
US6331543B1 (en) 1996-11-01 2001-12-18 Nitromed, Inc. Nitrosated and nitrosylated phosphodiesterase inhibitors, compositions and methods of use
ZA989356B (en) * 1997-10-16 1998-11-16 Isis Pharma Gmbh Pharmaceutical preparations
DE19745622A1 (de) * 1997-10-16 1999-04-22 Isis Pharma Gmbh Neue Salpetersäureester des Pentaerythrits
JP5187991B2 (ja) * 1997-10-17 2013-04-24 アーク・セラピューティックス・リミテッド レニン−アンジオテンシン系の阻害剤の使用
US6472425B1 (en) 1997-10-31 2002-10-29 Nitromed, Inc. Methods for treating female sexual dysfunctions
AU5503199A (en) * 1998-06-24 2000-01-10 Alpharma-Isis Gmbh And Co. Kg Analytic substrates and antioxidative agents
US6465463B1 (en) 1999-09-08 2002-10-15 Nitromed, Inc. Methods of treating and preventing congestive heart failure with hydralazine compounds and isosorbide dinitrate or isosorbide mononitrate
AU780261B2 (en) 1999-10-29 2005-03-10 Nitromed, Inc. Methods of treating vascular diseases characterized by nitric oxide insufficiency
US7537785B2 (en) 1999-10-29 2009-05-26 Nitromed, Inc. Composition for treating vascular diseases characterized by nitric oxide insufficiency
US7235237B2 (en) 1999-10-29 2007-06-26 Nitromed, Inc. Methods of treating vascular diseases characterized by nitric oxide insufficiency
US7708989B2 (en) 1999-10-29 2010-05-04 Nitromed, Inc. Methods of treating vascular diseases characterized by nitric oxide insufficiency
WO2008124505A2 (en) * 2007-04-05 2008-10-16 Ironwood Pharmaceuticals,Inc. Soluble guanylate cyclase (sgc) modulators for treatment of lipid related disorders
US9365574B2 (en) * 2010-05-27 2016-06-14 Merck Sharp & Dohme Corp. Soluble guanylate cyclase activators
RU2467748C1 (ru) * 2011-08-08 2012-11-27 Федеральное государственное автономное образовательное учреждение высшего профессионального образования "Белгородский государственный национальный исследовательский университет" Производное 3-(2,2,2-триметилгидразиний)пропионата - глицинат 3-(2,2,2-триметилгидразиний)пропионат калия, обладающее эндотелиопротекторной активностью

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR984523A (fr) * 1949-02-10 1951-07-06 Phosphate de trinitro-triéthanolamine et procédé de préparation
DE1695897C3 (de) * 1966-07-04 1979-02-15 Takeda Chemical Industries Ltd N-Acyl-sydnonimine, deren Salze, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
US3886186A (en) * 1971-04-29 1975-05-27 American Home Prod Mononitrate esters of 1,4:3,6-dianhydro-d-glucitol
GB1356374A (en) * 1971-04-29 1974-06-12 American Home Prod Mononitrate esters of 1,3 3,6-dianhydro-d-glucitol
DE2532124C3 (de) * 1975-07-18 1979-04-19 Cassella Ag, 6000 Frankfurt Verfahren zur Herstellung von 4-Amino-morpholin
US4200640A (en) * 1976-04-02 1980-04-29 Chugai Seiyaku Kabushiki Kaisha Nitric ester of N-(2-hydroxyethyl)nicotinamide and pharmaceutical use
DE2623800C3 (de) * 1976-05-28 1978-11-23 Sanol Schwarz-Monheim Gmbh, 4000 Duesseldorf Obersättigte wässerige Isosorbiddinitrat-Lösung, Herstellungsverfahren und Verwendung
US4065488A (en) * 1977-02-24 1977-12-27 American Home Products Corporation Process for preparing 1,4:3,6-dianhydro-D-glucitol 2-nitrate
DE2903927C2 (de) * 1979-02-02 1981-03-12 Sanol Schwarz-Monheim Gmbh, 4019 Monheim Verfahren zur selektiven Herstellung von Isosorbid-5-nitrat
DE3028873C2 (de) * 1980-07-30 1983-10-27 Boehringer Mannheim Gmbh, 6800 Mannheim Verfahren zur Herstellung von 1,4 zu 3,6-Dianhydro-D-glucit-5-nitrat (Isosorbid-5-nitrat)
DE3102947A1 (de) * 1981-01-29 1982-09-02 Heinrich Mack Nachf., 7918 Illertissen Verfahren zur herstellung von isosorbid-5-nitrat
FR2500835A1 (fr) * 1981-02-27 1982-09-03 Poudres & Explosifs Ste Nale Procede de synthese des mononitrates d'isosorbide
DE3117612A1 (de) * 1981-05-05 1982-11-25 Cassella Ag, 6000 Frankfurt Verfahren zur herstellung von isosorbid-5-nitrat
DE3124410A1 (de) * 1981-06-22 1983-01-05 Heinrich Mack Nachf., 7918 Illertissen Verfahren zur herstellung von isosorbid-2-nitrat
JPS5910513A (ja) * 1982-07-12 1984-01-20 Nitto Electric Ind Co Ltd 医薬製剤
DE3325652A1 (de) * 1983-07-15 1985-01-24 Dr. Rentschler Arzneimittel Gmbh & Co, 7958 Laupheim Feste, stabile isosorbid-5-mononitrat enthaltende arzneimittelzubereitungen und verfahren zu ihrer herstellung
DE3328094A1 (de) * 1983-08-04 1985-02-21 H. Trommsdorff GmbH & Co, 5110 Alsdorf Phlegmatisierte pharmazeutische zubereitung von explosionsfaehigen salpetersaeureestern
DE3479800D1 (en) * 1983-11-25 1989-10-26 Toshin Chemical Co A method for the preparation of isosorbide-5-nitrate and sodium isosorbide-5-nitrate hydrate as a precursor thereof
DD244980A1 (de) * 1985-12-18 1987-04-22 Isis Chemie Zwickau Veb Verfahren zur herstellung von n-morpholinoaminoacetonitril und dessen hydrochlorid
DD293492A5 (de) * 1987-11-26 1991-09-05 Isis-Chemie Gmbh,De Verfahren zur herstellung einer glyceroltrinitrat-arzneiform mit gleichmaessig verzoegerter arzneistofffreisetzung
US5284872A (en) * 1989-09-12 1994-02-08 Schwarz Pharma Ag Nitrato alkanoic acid derivatives, methods for their production, pharmaceutical compositions containing the derivatives and medicinal uses thereof
DE4007705C1 (lt) * 1990-03-10 1991-09-26 G. Pohl-Boskamp Gmbh & Co. Chemisch-Pharmazeutische Fabrik, 2214 Hohenlockstedt, De
DE4038203A1 (de) * 1990-11-30 1992-06-04 Kali Chemie Pharma Gmbh Pharmazeutische spray-zubereitungen mit coronaraktiven wirkstoffen
US5385937A (en) * 1991-04-10 1995-01-31 Brigham & Women's Hospital Nitrosation of homocysteine as a method for treating homocysteinemia

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007507451A (ja) * 2003-10-03 2007-03-29 レイサー ソシエダッド アノニマ 環状糖の二硫化物、硫化物、スルホキシド及びスルホン誘導体とその使用方法
JP2011012081A (ja) * 2003-10-03 2011-01-20 Lacer Sa 環状糖の二硫化物、硫化物、スルホキシド及びスルホン誘導体とその使用
JP4809769B2 (ja) * 2003-10-03 2011-11-09 レイサー ソシエダッド アノニマ 環状糖の二硫化物、硫化物、スルホキシド及びスルホン誘導体とその使用方法
JP2013082693A (ja) * 2011-09-28 2013-05-09 Univ Of Tokushima ニトロソニフェジピン誘導体を有効成分とする動脈硬化症治療剤

Also Published As

Publication number Publication date
SK121896A3 (en) 1998-10-07
IS4365A (is) 1996-09-25
LT4310B (lt) 1998-03-25
LV11666A (lv) 1997-02-20
CA2186783A1 (en) 1995-10-12
NO964102L (no) 1996-09-27
LV11666B (en) 1997-06-20
PL316528A1 (en) 1997-01-20
HU220165B (hu) 2001-11-28
HU9602671D0 (en) 1996-11-28
AU698359B2 (en) 1998-10-29
AU2134595A (en) 1995-10-23
FI963883A (fi) 1996-09-27
HUT76676A (en) 1997-10-28
DE4410997A1 (de) 1995-10-26
CN1150387A (zh) 1997-05-21
BG63073B1 (bg) 2001-03-30
LT96148A (en) 1997-12-29
DE19580261D2 (de) 1997-05-28
BG100930A (en) 1997-07-31
MX9604434A (es) 1997-12-31
EE9600139A (et) 1997-04-15
FI963883A0 (fi) 1996-09-27
CZ283696A3 (cs) 1998-03-18
NO964102D0 (no) 1996-09-27
EP0752858A1 (de) 1997-01-15
WO1995026725A1 (de) 1995-10-12
SI9520047A (en) 1997-06-30

Similar Documents

Publication Publication Date Title
JPH09510979A (ja) 内皮性機能障害の予防および治療用医薬製剤および医薬品
US5973011A (en) Pharmaceutical preparations and medicaments for the prevention and treatment of endothelial dysfunction
AU705002B2 (en) Method and formulation of stimulating nitric oxide synthesis
WO1996010910A9 (en) Method and formulation of stimulating nitric oxide synthesis
US20080300253A1 (en) Treatment of inflammatory disorders with praziquantel
CA2334973A1 (en) Use of nitric oxide scavengers to treat side effects caused by therapeutic administration of sources of nitric oxide
CA2875522A1 (en) Dosage forms and related therapies
CZ299162B6 (cs) Farmaceutický prípravek a souprava
US4416893A (en) Substituted 1,2,5-oxadiazole-2-oxides in human cardiovascular system disease
WO1994016740A1 (en) The use of nitric oxide-delivering compounds for the treatment or prevention of alcoholic liver injury
JP2004500344A (ja) 低酸素分圧状態における内因性一酸化窒素の合成
US6248895B1 (en) Benzofuroxan compound, method of preparation, pharmaceutical composition and method of treatment using the same
JP2001504446A (ja) 血管内皮細胞の損傷から生じる疾患を治療・予防するための医薬品
CN114699401A (zh) 异鼠李素在制备胸主动脉血管舒张药物中的用途
EP1140081A2 (en) Improving mental performance by increasing brain insulin sensitivity
US20080033019A1 (en) Cholesterol lowering drug combination
GB2084017A (en) Pharmaceutical compositions, effective against coronary heart disease and hypertension
JP2532918B2 (ja) グアニジノ安息香酸誘導体を有効成分として含有する抗動脈硬化剤
WO2018139477A1 (ja) ＮＯおよびＮＯ－ｐａｔｈｗａｙ刺激によるエリスロポエチン受容体を標的とした腎性貧血に対する新規治療薬
WO2011000562A1 (en) Eltoprazine for the treatment of certain movement disorders
EP1710243A1 (en) Therapeutic agent for vasospasm accompanying bypass operation
GB2146899A (en) Treatment of psychomotor excitement